ArticleCancer control : journal of the Moffitt Cancer Center
Why smokeless tobacco control needs to be strengthened?
Article in Cancer control : journal of the Moffitt Cancer Center. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Article
- Prevalence and correlates of nicotine dependence among the construction site workers at IGIMS, Patna.Journal of family medicine and primary care · 2022Article
- A public policy analysis with key stakeholders' insights to understand India's compliance with the WHO framework convention on tobacco control.Ecancermedicalscience · 2022Article
- Smokeless tobacco consumption and its association with tobacco control factors in the Western Pacific Region: results from the Global Youth Tobacco Survey 2015-2019.Epidemiology and health · 2022Article
- Global burden of disease due to smokeless tobacco consumption in adults: an updated analysis of data from 127 countries.BMC medicine · 2020Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tobacco menace is responsible for significant mortality and morbidity worldwide. Smokeless tobacco (SLT) is consumed in more than 140 countries, thus is emerging as a global problem. Several adverse health outcomes like oropharyngeal, oesophageal, and pancreatic cancers; oral potentially malignant lesions; diabetes mellitus; cardiovascular diseases; mental illness; osteopenia; low birth weight; preterm births; small for gestation age babies; and stillbirths are attributed to SLT usage. Smokeless tobacco products vary greatly in types, constituents, packaging, forms, addiction, and harm potential, and thus are challenging to study and control. Involvement of both formal and informal sector in SLT production and sales further add to the complexities. The problem of SLT is usually understated and less researched upon. This paper summarizes the existing knowledge and provides evidence to strengthen the case against the SLT, stressing on the need to enhance the SLT control across the globe.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.